Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based healthcare company AstraZeneca has announced that the once-daily formulation Seroquel XR and Seroquel have received approval under the European mutual recognition procedure for new indications in bipolar disorder.
Subscribe to our email newsletter
Seroquel XR and Seroquel have been approved for the treatment of major depressive episodes in bipolar disorder. Additionally, Seroquel XR has been licensed for moderate to severe manic episodes in bipolar disorder.
This follows the October 2008 approval of Seroquel XR in similar indications by the FDA. As a result of these new indications for adult patients, Seroquel (both formulations) is currently the only atypical antipsychotic approved to treat the spectrum of mood episodes associated with bipolar disorder and the only licensed treatment for bipolar depression in the EU, the company said.
AstraZeneca will move forward with obtaining local approvals with the 17 member states that take part in the mutual recognition procedure.